Trial reportNeurogastroenterology and motility2026
ReFerm® a Fermented Oat Gruel Composition, Improves Colonic Barrier Function and Modulates Tricellulin Expression in Patients With Irritable Bowel Syndrome.
Trial report in Neurogastroenterology and motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIntestinal barrier dysfunction has been implicated in the pathophysiology of irritable bowel syndrome (IBS), contributing to increased permeability, low-grade inflammation, and symptom generation. Microbial compositions are known to improve epithelial barrier function, although the underlying molecular mechanisms remain elusive. The aim was to investigate the effects of the fermented oat gruel preparation ReFerm® on colonic barrier function and tight junction protein expressions in patients with IBS.
methodsColonic biopsies from patients with IBS were mounted in Ussing chambers to assess the direct effects of ReFerm® on epithelial permeability. In parallel, biopsies from patients treated with ReFerm® or placebo by enema were analyzed for the expression of multiple tight junction proteins using Western blotting and confocal microscopy. In vitro effects were further evaluated in Caco-2 cells. KEY
resultsReFerm® reduced both paracellular and transcellular permeability when added directly to biopsies mounted in Ussing chambers, compared with unstimulated biopsies. This effect was accompanied by increased expression of the tight junction protein tricellulin at tricellular junctions. In vitro experiments in Caco-2 cells supported these findings, demonstrating direct effects of ReFerm® on epithelial barrier properties. CONCLUSIONS AND INTERFERENCES: ReFerm® strengthens colonic barrier integrity in the gut mucosa of patients with IBS, potentially through modulation of the tight junction protein tricellulin. These findings provide mechanistic insight into the barrier-protective effects of fermented oat interventions such as ReFerm® and support the potential therapeutic role in IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.